Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 133

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 133
---
Evaluation
of Disclosure Controls and Procedures

Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of December 31,
2024, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).
Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and
procedures were effective at the reasonable assurance level as of December 31, 2024.

Management’s
Annual Report on Internal Control over Financial Reporting

Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Exchange Act.

Our
management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth
in “Internal Control- Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our assessment, our management concluded that as of December 31, 2024, our internal control over financial reporting was effective.

71

Attestation
Report of the Independent Registered Public Accounting Firm

This
Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting due to an exemption provided to issuers that are not “large accelerated filers” nor “accelerated filers”
under applicable SEC rules.

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

Item
9B. Other Information.

During
the three months ended December 31, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of
the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”
as each term is defined in Item 408(a) of Regulation S-K.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not
applicable.

PART
III

Item
10. Directors and Executive Officers